Exhibit 99.01
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2018 and Provides Initial 2019 Outlook
SAN DIEGO, CA - (BUSINESS WIRE-January 7, 2019) – DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2018 to exceed $331 million, an increase of at least 50% over the fourth quarter of 2017. For fiscal 2018, total preliminary, unaudited revenue is expected to exceed $1.025 billion, an increase of more than 42% over 2017.
“We are thrilled with Dexcom’s full-year performance in 2018, with growth exceeding our original expectations by a significant margin and driving us to a historic milestone of more than $1 billion in annual revenues. Our success in 2018 was driven by increasing awareness of the importance of CGM in managing diabetes, supported by the approval and launch of Dexcom’s G6 CGM platform both in the U.S. and internationally,” said Kevin Sayer, Dexcom’s Chairman, President and CEO. “Looking ahead to 2019, we are confident in our position to continue delivering strong results.”
2019 Outlook
For 2019, Dexcom currently anticipates total revenue of approximately $1.175 billion to $1.225 billion, representing expected growth of approximately 15% to 20% over 2018. This growth outlook is driven by strong growth in sensor volumes, continued international expansion, shifting channel mix and overall market dynamics.
Dexcom will provide further details related to its 2019 financial expectations on the fourth quarter earnings call.
Fourth Quarter 2018 Financial Results Conference Call
Dexcom will report its audited full fourth quarter and fiscal 2018 financial results on Thursday, February 21, 2019 after the close of market. Management is currently scheduled to host a conference call at 4:30 p.m. (Eastern Time) that day. More details will be provided later.
